Atrial Arrhythmias in Patients with Severe COVID-19
Table 2
Heart rate, arrhythmias, cardiomyocyte injury marker, and death in patients with bacterial pneumonia and COVID-19 patients.
Variable
Bacterial pneumonia (N = 84)
COVID-19 patients (nonstandardization) (N = 84)
COVID-19 patients (standardization) (N = 84)
valuea
Record time (h)
24
41.60 (25.90, 66.00)
24.00
<0.01
Total heart rate (beats)
100207 (92309.30, 11123)
208850 (128049.30, 302796.50)
115913.50 (108373.00, 129454.60)
<0.01
Maximum heart rate (bpm)
127.20 ± 22.70
129.50 ± 21.60
129.50 ± 21.60
0.73
Minimum heart rate (bpm)
48.30 ± 8.50
57.90 ± 10.50
57.90 ± 10.50
<0.01
Mean heart rate (bpm)
70.80 ± 10.70
82 ± 10.70
82 ± 10.70
<0.01
PAC (beats)
18 (4.50, 251.50)
30 (4, 329)
16.190 (2.70, 3943.40)
0.06
NSAT (n)
1 (0, 3.00)
0 (0, 3.80)
0 (0, 2.40)
0.14
AF (n)
3 (3.60)
4 (4.80)
4 (4.80)
1.00
PVC (beats)
2.5 (0, 35)
8 (1, 149)
4.39 (0.40, 91.40)
0.37
NSVT (n)
0 (0, 0)
0 (0, 0)
0 (0, 0)
0.30
SVT (n)
0
0
0
1.00
PSVT (n)
0
0
0
1.00
AVB (n)
0
3 (3.60)
3 (3.60)
0.25
Data are expressed as mean (SD) or median (IQR) for continuous variables and number (%) for categorical variables. AF, atrial fibrillation; AVB, atrioventricular block; COVID-19, novel coronavirus disease 2019; PAC, premature atrial contracts; PSVT, paroxysmal supraventricular tachycardia; PVC, premature ventricular contracts; NSAT, nonsustained atrial tachycardia; NSVT, nonsustained ventricular tachycardia; SVT, sustained ventricular tachycardia. aStatistical differences between the COVID-19 patients (standardization) and COVID-19 patients (nonstandardization) groups.
